Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas
Top Cited Papers
- 14 February 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (4), 708
- https://doi.org/10.1200/jco.2000.18.4.708
Abstract
PURPOSE: Little progress has been made in the treatment of adult high-grade gliomas over the last two decades, thus necessitating a search for novel therapeutic strategies. Malignant gliomas are va...Keywords
This publication has 28 references indexed in Scilit:
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growthNature, 1994
- The basis for current treatment recommendations for malignant gliomasJournal of Neuro-Oncology, 1994
- Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomasJournal of Neurosurgery, 1992
- Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growthNature, 1990
- Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisoneJournal of Neurosurgery, 1990
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Criteria for evaluating patients undergoing chemotherapy for malignant brain tumorsJournal of Neurosurgery, 1977
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971